Cirdan Ltd, founded in 2010 by Dr. Hugh Cormican and Stephen Dunniece in Lisburn, Ireland, is revolutionizing healthcare diagnostics with headquarters in the UK and offices in Canada and Australia, Cirdan provides cutting-edge laboratory information systems (LIS) that streamline workflows in clinical settings. Its impact spans 20 countries and six continents, transforming diagnostics in over 200 clinical laboratories and hospitals 

Innovative Product & Services:
Their flagship product, ULTRA LIS, is a next-gen solution built to scale—whether for small labs or large multi-site diagnostic centers It enhances efficiency, ensuring healthcare professionals deliver faster, more accurate diagnoses, ultimately improving patient care Cirdan Ltd also offers software and imaging solutions that speed up disease diagnosis and treatment timelines, making healthcare systems more efficient.

Leaders Driving Impact:
CEO Dr. Hugh Cormican leads the innovation journey, with confidence in global expansion fueled by strategic investors. He remarked, “The backing of 57 Stars and the Investment Fund for Northern Ireland reflects the potential of our technology to make a significant healthcare impact.”

Transforming Healthcare Delivery

Cirdan’s technology empowers healthcare professionals to deliver more accurate and timely diagnoses, leading to improved patient outcomes and healthcare efficiency. By leveraging advanced software and imaging solutions, Cirdan’s products enhance diagnostic capabilities and expedite the identification of diseases.

Global Impact

Cirdan’s solutions are already making a significant impact on healthcare delivery in over 20 countries across six continents. With its headquarters in the UK and offices in Canada and Australia, Cirdan is poised to become a global leader in laboratory information systems.

A Bright Future

The recent investment from 57 Stars and IFNI will enable Cirdan to accelerate its growth trajectory. The funding will be used to expand its team of experts, enhance product development, and strengthen its global presence.

Cirdan CEO Hugh Cormican expressed his enthusiasm for the future, stating, “This investment is a testament to the value and potential of our technology. We are confident in our ability to scale our solutions globally and make a significant impact on healthcare.”

Funding Details

Cirdan has secured £7.5 million in funding from 57 Stars and the Investment Fund for Northern Ireland. This investment will fuel the company’s global expansion and product innovation.